Study of the Glutaminase Inhibitor CB-839 in Leukemia
A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Relapsed and/or Treatment-Refractory Leukemia
Sponsor: Calithera Biosciences, Inc
A PHASE1 clinical study on Acute Lymphocytic Leukemia (ALL) and Acute Myeloid Leukemia (AML), this trial is completed. The trial is conducted by Calithera Biosciences, Inc and has accumulated 6 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
Status: Recruiting → Completed
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Mar 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Calithera Biosciences, Inc
For direct contact, visit the study record on ClinicalTrials.gov .